Year: 2018
Type: article
Abstract: Among all patients with myasthenia gravis (MG), 10 to 15% are considered to be refractory to (expanded) standard treatments. Current international consensus guidelines for the management of myasthenia gravis recommend referral of refractory MG patients to centers with expertise in the treatment of MG and chronic intravenous immunoglobulin therapy or plasmapheresis. Here we briefly summarize current approaches to overcome refractory myasthenia gravis.
Source: Neurology International Open
Authors: Sarah Hoffmann, Andreas Meisel
Institution: Charité - Universitätsmedizin Berlin
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W2788009983